This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due to their successful diabetes and weight loss medications. They are also big players in the burgeoning GLP-1 weight loss market, and investors are paying large premiums for these stocks based on their potential.But what's intriguing is that the potential may be even bigger than what analysts and investors are expecting. And that's because there may be even greater benefits associated with maintaining a healthier weight than the ones that are known today. One study suggests that it may even help reduce the risk of developing Alzheimer's.There are many illnesses and conditions which are associated with being obese, which is why it's paramount for many patients to maintain a healthy weight. But one particularly concerning illness which you may not have considered to be associated with weight gain is Alzheimer's. The disease robs people of their memories, and since it's a neurological issue, many people may not think that carrying a lot of weight could put them at risk for that disease, but a new study suggests that could indeed be the case.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool